Feedback / Questions
MHB018A - Minghui Pharma
https://www.manilatimes.net/2025/12/15/tmt-newswire/pr-newswire/minghui-pharmaceutical-announces-fda-clearance-of-ind-to-initiate-global-phase-trials-of-mhb018a-a-subcutaneous-single-domain-igf-1r-antibody-in-thyroid-eye-disease/2243338/amp
Dec 15, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next